Klox to price its IPO of 4.8 million shares between $13.00 and $15.00

UBS is the bookrunner; Canaccord Genuity and Needham also will assist

By Devika Patel

Knoxville, Tenn., April 27 – Klox Technologies Inc. will sell 4.8 million common shares in its initial public offering with a 30-day greenshoe of 720,000 additional shares, according to a Form S-1/A filed Monday with the Securities and Exchange Commission. The company has registered up to $82.8 million of stock for the deal.

The shares will be sold at a price expected to fall between $13.00 and $15.00 per share.

UBS Securities LLC is the bookrunner. Canaccord Genuity Inc. and Needham & Co., LLC are the lead managers, and National Bank of Canada Financial Inc. is the co-manager.

Proceeds will be used for research and development, clinical trials, commercial sales and marketing activities, working capital requirements and other general corporate purposes.

The pharmaceutical company is based in Laval, Quebec. The company intends to list its common stock on the Nasdaq under the symbol “KLOX.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.